Completed PHASE1 INTERVENTIONAL 2-arm NCT01309763

Safety and Tolerability of AFFITOPE AD03 (MimoVax)

A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess the Tolerability and Safety of Repeated Administrations of a Single-dose of AFFITOPE AD03 to Alzheimer's Disease Patients

Sponsor: Affiris AG

Conditions Alzheimer's Disease

Interventions AFFITOPE AD03 AFFITOPE AD03 + Alum

Updated 5 times since 2017 Last updated: Dec 19, 2011 Started: Oct 31, 2010 Primary completion: Sep 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01309763, this PHASE1 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Affiris AG, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affiris AG

Data source: Affiris AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria